2-amino-bicyclo3.1.0 hexane-2,6-dicarboxylic ester derivative
CA 2530706 C · Owner: Sakagami, Kazunari · Inventors: Ohta, Hiroshi; Nakazato, Atsuro; Sakagami, Kazunari
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A drug effective for the treatment and prevention of psychiatric disorders such as , schizophrenia, anxiety and related ailments thereof depression, bipolar , disorder and , epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors , and shows high activity in oral administraiton. A 2-amino-bicyclo 3.1.0 hexane-2,6-dicarboxylic ester derivative represented by , formula I, (see formula I) , wherein R1 and R2 are identical or different and each represents a hydrogen , atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y , represents -OCHR3R4 or the like (wherein R3 and R4 are identical or different and each , represents a …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 25, 2004 and granted November 27, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 25, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 25, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.